Detalles de la búsqueda
1.
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.
Blood
; 143(16): 1565-1575, 2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38252906
2.
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Blood
; 139(22): 3278-3289, 2022 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35196370
3.
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
Am J Hematol
; 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38700035
4.
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Am J Hematol
; 98(3): 449-463, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36594167
5.
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Br J Cancer
; 117(9): 1258-1268, 2017 Oct 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-28859059
6.
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
J Immunother Cancer
; 12(3)2024 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38519055
7.
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.
J Transl Med
; 11: 259, 2013 Oct 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-24131779
8.
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
Clin Lymphoma Myeloma Leuk
; 23(7): 515-526, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37076367
9.
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study.
Blood Adv
; 6(4): 1232-1242, 2022 02 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34972202
10.
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Lancet Haematol
; 9(5): e327-e339, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35366963
11.
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Curr Hematol Malig Rep
; 16(1): 72-81, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33619641
12.
Impact of Insurance Status on Survival Outcomes in Adults With Acute Lymphoblastic Leukemia (ALL): A Single-center Experience.
Clin Lymphoma Myeloma Leuk
; 20(11): e890-e896, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32773302
13.
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
JAMA Oncol
; 4(5): 712-716, 2018 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29470582
14.
Influenza Adherence Tool Kit: Implementation and Evaluation Among Allogeneic Hematopoietic Transplantation Recipientsâ©.
Clin J Oncol Nurs
; 21(3): 339-344, 2017 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28524898
15.
Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
J Clin Oncol
; 21(8): 1466-71, 2003 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12697868
16.
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.
Mol Cancer Ther
; 14(7): 1532-9, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25931518
17.
Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.
Clin Breast Cancer
; 14(3): 169-76, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24393852
18.
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Lung Cancer
; 83(2): 219-23, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24388167
19.
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.
Cancer Chemother Pharmacol
; 72(4): 897-908, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23949430
20.
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Cancer Chemother Pharmacol
; 70(6): 891-8, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23053255